Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 13/20 | 0.53 |
| ▸ | CTSS | P25774 | 10/20 | 0.53 |
| ▸ | CTSB | P07858 | 10/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | CTSV | O60911 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737501 | 0.91 | CTSL (0.63) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6737504 | 0.91 | CTSL (0.63) | CTSLCTSSCTSBCTSK | |
| SCHEMBL1557334 | 0.91 | CTSL (0.55) | CTSLCTSSCTSBCTSKCTSV | |
| SCHEMBL6737932 | 0.91 | CTSL (0.54) | CTSLCTSSCTSBCTSKCTSV | |
| SCHEMBL6737536 | 0.89 | CTSB (0.54) | CTSLCTSSCTSBCTSK | |
| SCHEMBL1557818 | 0.87 | CTSS (0.52) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6744795 | 0.87 | CTSL (0.57) | CTSLCTSSCTSBCTSK | |
| SCHEMBL1558022 | 0.87 | CTSL (0.57) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6062909 | 0.87 | CTSS (0.45) | CTSLCTSSCTSBCTSKALDH1A1 | |
| SCHEMBL6062036 | 0.87 | CTSB (0.51) | CTSLCTSSCTSBCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | claimed |
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1212302-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019796-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | CTSL 10/4885CTSS 1/4885CTSB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.